Meeting
2016 ASCO Annual Meeting
Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1.
Authors
Aung Naing
Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX
Aung Naing , Kyriakos P. Papadopoulos , Jeffrey R. Infante , Deborah Jean Lee Wong , Karen A. Autio , Patrick Alexander Ott , Gerald Steven Falchook , Manish R. Patel , Shubham Pant , Amita Patnaik , John B Mumm , Melinda Whiteside , Ivan H Chan , Johanna C. Bendell , Todd Michael Bauer , Filip Janku , Rivka R Colen , Nizar M. Tannir , Peter Van Vlasselaer , Martin Oft
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02009449
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3018)
DOI
10.1200/JCO.2016.34.15_suppl.3018
Abstract #
3018
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC.
First Author: Deborah Jean Lee Wong
Poster
2017 ASCO Annual Meeting
PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA‑4 refractory melanoma.
First Author: Aung Naing
Poster
2017 ASCO Annual Meeting
Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer.
First Author: Aung Naing
Poster
2020 ASCO Virtual Scientific Program
Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).
First Author: Martin Edelman